Ocular Therapeutix (OCUL) EPS (Weighted Average and Diluted) (2018 - 2026)
Ocular Therapeutix's quarterly EPS (Weighted Average and Diluted) came in at -$0.4 in Q1 2026, down 5.26% year-on-year from -$0.42 in Q1 2025, and down 48.15% quarter-over-quarter from -$0.27 in Q4 2025.
Ocular Therapeutix has reported EPS (Weighted Average and Diluted) for 9 years, with the latest figure at -$0.4 in Q1 2026.
- For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) fell 5.26% year-over-year to -$0.4; the trailing twelve-month figure through Mar 2026 stood at -$1.44 (down 26.32% YoY), and the FY2025 full-year result was -$1.42, down 16.39% from the prior year.
- EPS (Weighted Average and Diluted) for Q1 2026 stood at -$0.4, down from -$0.27 in the prior quarter.
- The five-year high for EPS (Weighted Average and Diluted) was -$0.22 in Q1 2022, with the low at -$0.49 in Q1 2024.
- Average EPS (Weighted Average and Diluted) over 5 years is -$0.31, with a median of -$0.27 recorded in 2025.
- Year-over-year, EPS (Weighted Average and Diluted) tumbled 77.27% in 2023 and grew 22.45% in 2025.
- Tracing OCUL's EPS (Weighted Average and Diluted) over 5 years: stood at -$0.24 in 2022, then decreased by 4.17% to -$0.25 in 2023, then fell by 12.0% to -$0.28 in 2024, then climbed by 3.57% to -$0.27 in 2025, then slumped by 48.15% to -$0.4 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.4 (Q1 2026), -$0.27 (Q4 2025), and -$0.38 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -4.43 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3,086.42 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 0.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 4.02 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 6.75 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.51 |
| 10 | Ocular Therapeutix | 1.99 Bn | 1.99 Bn | 9.46 Mn | -0.40 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.40 |
| Dec 31, 2025 | -0.27 |
| Sep 30, 2025 | -0.38 |
| Jun 30, 2025 | -0.39 |
| Mar 31, 2025 | -0.38 |
| Dec 31, 2024 | -0.28 |
| Sep 30, 2024 | -0.22 |
| Jun 30, 2024 | -0.26 |
| Mar 31, 2024 | -0.49 |
| Dec 31, 2023 | -0.25 |
| Sep 30, 2023 | -0.25 |
| Jun 30, 2023 | -0.26 |
| Mar 31, 2023 | -0.39 |
| Dec 31, 2022 | -0.24 |
| Sep 30, 2022 | -0.31 |
| Jun 30, 2022 | -0.25 |
| Mar 31, 2022 | -0.22 |
| Dec 31, 2021 | -0.23 |
| Sep 30, 2021 | -0.23 |
| Jun 30, 2021 | -0.25 |
| Mar 31, 2021 | -0.24 |
| Dec 31, 2020 | -1.34 |
| Sep 30, 2020 | -0.21 |
| Jun 30, 2020 | -0.64 |
| Mar 31, 2020 | -0.41 |
| Dec 31, 2019 | -0.54 |
| Sep 30, 2019 | -0.45 |
| Mar 31, 2019 | -0.45 |
| Sep 30, 2018 | -0.38 |
| Mar 31, 2018 | -0.40 |